Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genome Study Strengthens Value of PSA Screening as Diagnostic Tool

By LabMedica International staff writers
Posted on 14 Feb 2017
Results of a genome-wide association study (GWAS) of prostate specific antigen (PSA) may lead to improvements that will increase the usefulness of measuring this biomarker for diagnosis of prostate cancer.

Prostate-specific antigen (PSA, also known as kallikrein III, seminin, semenogelase, gamma-seminoprotein and P-30 antigen) is a 34,000 molecular weight glycoprotein produced almost exclusively by the prostate gland. Prostate cancer can cause disruption of the prostate’s cellular architecture, which in turn can result in PSA leaking into circulating blood. PSA screening for prostate cancer has been used for over 20 years, but its use has declined recently because of concerns about over-diagnosis and over-treatment. This is because PSA levels can also be affected by benign prostatic hyperplasia (BPH), local inflammation or infection, prostate volume, age, and germline genetics.

Seeking to strengthen the foundations of the PSA assay, investigators at the University of California, San Francisco and colleagues at Kaiser Permanente performed a genome-wide association study (GWAS) involving 28,503 men from the Kaiser Permanente cohort and 17,428 men from additional replication cohorts, in the aggregate representing nearly half a million PSA tests going back to the 1990s.

The investigators reported that they detected 40 genome-wide significant single-nucleotide polymorphisms (SNPs): 19 novel, 15 previously identified for PSA (14 of which were also prostate cancer-associated), and six previously identified for prostate cancer only. Further analysis incorporating prostate cancer cases suggested that at least half of the 40 SNPs were PSA-associated independent of prostate cancer. The 40 SNPs explained 9.5% of PSA variation in non-Hispanic whites, and the remaining GWAS SNPs explained an additional 31.7%; this percentage was higher in younger men, supporting the genetic basis of PSA levels.

These findings provide important information about genetic markers for PSA that may improve prostate cancer screening, thereby reducing over-diagnosis and over-treatment.

"In the few years that PSA testing has become less popular, the use of the test has declined and the number of prostate cancer diagnoses has dropped," said senior author Dr. John Witte, professor of epidemiology, biostatistics, and urology at the University of California, San Francisco. "Disturbingly, some of the cases that are detected are now being diagnosed at a later stage, making successful treatment less likely. It is a big conundrum for the field. Despite the flaws of PSA testing, it does have value as a diagnostic tool. If we want to improve PSA as a useful diagnostic, we need to fold personalized genetics into medical decision-making. We need to be able to tell patients - this is a high PSA value for you, not just for the average person."

The study was published in the January 31, 2017, online edition of the journal Nature Communication.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.